[go: up one dir, main page]

PE20190976A1 - Anticuerpos de union a cd3 - Google Patents

Anticuerpos de union a cd3

Info

Publication number
PE20190976A1
PE20190976A1 PE2019000520A PE2019000520A PE20190976A1 PE 20190976 A1 PE20190976 A1 PE 20190976A1 PE 2019000520 A PE2019000520 A PE 2019000520A PE 2019000520 A PE2019000520 A PE 2019000520A PE 20190976 A1 PE20190976 A1 PE 20190976A1
Authority
PE
Peru
Prior art keywords
cdr2
cdr3
cdr1
seq
framework
Prior art date
Application number
PE2019000520A
Other languages
English (en)
Inventor
Nathan Trinklein
Schooten Wim Van
Shelley Force Aldred
Katherine Harris
Duy Pham
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of PE20190976A1 publication Critical patent/PE20190976A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se refiere a una proteina de union al antigeno especifica para las CD3, la cual comprende un dominio de cadena pesada variable que a su vez comprende secuencias de CDR1, CDR2 y CDR3 en un marco VH humano, donde la secuencia de CDR1 tiene la formula: G1 F2 T3 F4 X5 X6 Y7 A8; donde X5 y X6 son cualquier aminoacido; CDR2 (I1' S2' W3' N4' S5' G6' S7' I8') y CDR3 (A1'' K2'' D3'' S4'' R5'' G6'' Y7'' G8'' X9'' Y10'' X11'' X12'' G13'' G12'' A15'' Y16'', donde X9'', X11'' y X12'' son cualquier aminoacido; y un dominio de cadena ligera variable. Tambien se refiere a una composicion farmaceutica que comprende la proteina, un polinucleotido que codifica la proteina, un vector que comprende al polinucleotido, una celula que comprende al vector, a metodos de elaboracion, a un anticuerpo biespecifico que comprende una region variable de union a CD3 (contiene secuencias de CDR1, CDR2 y CDR3 de la SEQ ID NO:1 en un marco VH humano), un dominio de cadena ligera variable (contiene secuencias de CDR1, CDR2 y CDR3 de la SEQ ID NO:19 en un marco VL humano), y una region variable anti-BCMA monocatenaria (contiene secuencias de CDR1, CDR2 y CDR3 en las posiciones 26-33; 51-58; 97-108, respectivamente, de la SEQ ID NO:20 en configuracion individual o en tandem); y a su uso para el tratamiento de enfermedades como el cancer.
PE2019000520A 2016-09-14 2017-06-20 Anticuerpos de union a cd3 PE20190976A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662394360P 2016-09-14 2016-09-14
US201762491908P 2017-04-28 2017-04-28

Publications (1)

Publication Number Publication Date
PE20190976A1 true PE20190976A1 (es) 2019-07-09

Family

ID=61619675

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2019000520A PE20190976A1 (es) 2016-09-14 2017-06-20 Anticuerpos de union a cd3
PE2024000894A PE20241349A1 (es) 2016-09-14 2017-06-20 Anticuerpos de union a cd3

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2024000894A PE20241349A1 (es) 2016-09-14 2017-06-20 Anticuerpos de union a cd3

Country Status (32)

Country Link
US (4) US11505606B2 (es)
EP (3) EP3512549A4 (es)
JP (7) JP7030109B2 (es)
KR (5) KR20240044520A (es)
CN (3) CN109843325B (es)
AU (2) AU2017327723B2 (es)
BR (2) BR112019004873A2 (es)
CA (1) CA3036550A1 (es)
CL (4) CL2019000643A1 (es)
CO (1) CO2019003706A2 (es)
CR (3) CR20190198A (es)
DK (1) DK4050034T3 (es)
DO (3) DOP2019000059A (es)
EC (1) ECSP19026304A (es)
ES (1) ES2980623T3 (es)
FI (1) FI4050034T3 (es)
HR (1) HRP20240767T1 (es)
HU (1) HUE066651T2 (es)
IL (3) IL265321B2 (es)
LT (1) LT4050034T (es)
MX (4) MX2019002967A (es)
MY (1) MY200988A (es)
PE (2) PE20190976A1 (es)
PH (1) PH12019500545A1 (es)
PL (1) PL4050034T3 (es)
PT (1) PT4050034T (es)
RS (1) RS65595B1 (es)
SA (2) SA522431672B1 (es)
SI (1) SI4050034T1 (es)
UA (1) UA126384C2 (es)
WO (1) WO2018052503A1 (es)
ZA (1) ZA202203250B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230129583A (ko) * 2016-06-21 2023-09-08 테네오바이오, 인코포레이티드 Cd3 결합 항체
IL265321B2 (en) * 2016-09-14 2024-01-01 Teneobio Inc Cd3 binding antibodies
MX2019007379A (es) 2016-12-21 2019-09-18 Teneobio Inc Anticuerpos anti-bcma unicamente de cadena pesada.
IL271194B2 (en) 2017-06-20 2024-10-01 Teneobio Inc Anti-bcma heavy chain-only antibodies
EP3642236A1 (en) * 2017-06-20 2020-04-29 TeneoOne, Inc. Anti-bcma heavy chain-only antibodies
WO2019126756A1 (en) 2017-12-22 2019-06-27 Teneobio, Inc. Heavy chain antibodies binding to cd22
KR20200104364A (ko) * 2017-12-27 2020-09-03 테네오바이오, 인코포레이티드 Cd3-델타/엡실론 이형이량체 특이적 항체
LT3802608T (lt) 2018-05-24 2025-06-25 Janssen Biotech, Inc. Antikūnai prieš cd3 ir jų panaudojimas
MD3823665T2 (ro) 2018-07-19 2024-05-31 Regeneron Pharma Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
MX2021000708A (es) 2018-07-20 2021-03-25 Teneobio Inc Anticuerpos de cadena pesada que se unen al cd19.
US10867104B2 (en) * 2018-08-31 2020-12-15 Taiwan Semiconductor Manufacturing Company Ltd. Isolation circuit between power domains
AU2019367218A1 (en) 2018-10-26 2021-06-03 TeneoFour, Inc. Heavy chain antibodies binding to CD38
US12180298B2 (en) * 2019-04-05 2024-12-31 Teneobio, Inc. Heavy chain antibodies binding to PSMA
UY38748A (es) 2019-06-14 2021-01-29 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
AU2020298104A1 (en) * 2019-06-21 2022-02-24 Università Degli Studi Magna Graecia Catanzaro Monoclonal antibody targeting a unique cancer-associated epitope of CD43
US20230374130A1 (en) * 2019-07-30 2023-11-23 Qlsf Biotherapeutics, Inc. Bispecific anti lrrc15 and cd3epsilon antibodies
CN112574308A (zh) 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 靶向bcma的抗体、双特异性抗体及其用途
BR112022011824A2 (pt) 2019-12-18 2022-08-30 Teneofour Inc Anticorpos de cadeia pesada que se ligam a cd38
WO2021222578A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
JP7625007B2 (ja) 2020-04-29 2025-01-31 テネオバイオ， インコーポレイテッド 重鎖定常領域が修飾された多重特異性重鎖抗体
US20210403587A1 (en) 2020-04-29 2021-12-30 Teneobio, Inc. Methods of treating multiple myeloma
IL299027A (en) 2020-06-30 2023-02-01 Teneobio Inc Multispecific antibodies that bind BCMA
JP2023542257A (ja) 2020-09-16 2023-10-05 アムジェン インコーポレイテッド 癌の治療のために二重特異性ｔ細胞誘導分子の治療用量を投与する方法
EP3991796A1 (en) * 2020-10-27 2022-05-04 Lindis Blood Care GmbH An ex vivo method for removal of tumor cells from intra-operatively salvaged blood
TW202233684A (zh) 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
KR20230148828A (ko) 2021-02-25 2023-10-25 테네오바이오, 인코포레이티드 항-psma 항체 및 car-t 구조
EP4298129A1 (en) 2021-02-26 2024-01-03 Teneobio, Inc. Anti-muc1-c antibodies and car-t structures
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
BR112023020450A2 (pt) 2021-04-06 2024-01-23 Teneobio Inc Anticorpos anti-cd19 e estruturas car-t
CR20230525A (es) 2021-04-16 2024-02-19 Teneobio Inc Anticuerpos anti-cd20 y estructuras car-t
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
CN119569887A (zh) * 2021-06-24 2025-03-07 益科思特(北京)医药科技发展有限公司 结合bcma和cd3的双特异性抗体及其制备方法与应用
US20240376156A1 (en) * 2021-07-13 2024-11-14 University Of Washington Multiple de novo designed protein binding proteins
WO2023004197A1 (en) 2021-07-23 2023-01-26 Teneoten, Inc. Heavy chain antibodies binding to hepatitis b surface antigen
AU2022326063A1 (en) 2021-08-09 2024-03-14 Harbour Biomed (Shanghai) Co., Ltd Cldn18.2-targeting antibody, bispecific antibody and use thereof
US20230192843A1 (en) 2021-10-14 2023-06-22 Teneobio, Inc. Mesothelin binding proteins and uses thereof
EP4561613A1 (en) 2022-07-27 2025-06-04 Teneobio, Inc. Mesothelin binding proteins and uses thereof
AU2023356984A1 (en) 2022-10-05 2025-03-20 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
WO2024178056A1 (en) 2023-02-21 2024-08-29 Teneobio, Inc. C-kit binding proteins, chimeric antigen receptors, and uses thereof
KR20240139569A (ko) * 2023-03-13 2024-09-23 머스트바이오 주식회사 신규한 cd3 결합항체 및 이를 포함한 다중특이 항체
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5968509A (en) 1990-10-05 1999-10-19 Btp International Limited Antibodies with binding affinity for the CD3 antigen
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
EA007471B1 (ru) 1999-01-07 2006-10-27 Займодженетикс, Инк. Растворимый рецептор br43x2 и способы его применения
RS51157B (sr) 1999-08-17 2010-10-31 Biogen Idec Ma Inc. Baff receptor (bcma), imunoregulatorni agens
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2001024812A1 (en) 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
KR20020093029A (ko) 2000-04-11 2002-12-12 제넨테크, 인크. 다가 항체 및 그의 용도
JP2003533218A (ja) 2000-05-12 2003-11-11 アムジエン・インコーポレーテツド Ａｐｒｉｌ／ｇ７０、ｂｃｍａ、ｂｌｙｓ／ａｇｐ−３及びｔａｃｉに関する物質の組成物及び使用方法
AU2002246737B2 (en) * 2000-12-29 2007-03-01 Savient Pharmaceuticals, Inc. Specific human antibodies for selective cancer therapy
CA2438682A1 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
CN1195779C (zh) 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 抗人卵巢癌抗人cd3双特异性抗体
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
US7608429B2 (en) 2002-10-31 2009-10-27 Genentech, Inc. Methods and compositions for increasing antibody production
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
CA2522586C (en) 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
JP5010281B2 (ja) 2003-05-31 2012-08-29 マイクロメット アクツィエン ゲゼルシャフト Ｅｐｃａｍに対する二重特異性抗体を含む薬学的組成物
DK1673398T3 (da) 2003-10-16 2011-04-18 Micromet Ag Multispecifikke, deimmuniserede CD3-bindere
SI1691837T1 (sl) * 2003-12-10 2012-11-30 Medarex Inc Ip protitelesa in njihova uporaba
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
MXPA06014075A (es) 2004-06-03 2007-03-15 Novimmune Sa Anticuerpos anti-cd3 y metodos de uso de los mismos.
EP2311874B1 (en) 2004-07-22 2017-05-31 Erasmus University Medical Center Rotterdam Binding molecules
RU2492186C2 (ru) 2005-02-18 2013-09-10 Медарекс Ллс Выделенное анти-cd30 антитело (варианты), хозяйская клетка, способ получения химерного или гуманизированного варианта анти-cd30 антител (варианты), способ ингибирования роста клеток cd30+ и способ ингибирования роста опухолевых клеток, экспрессирующих cd30
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP2009507838A (ja) 2005-09-12 2009-02-26 ノビミューン エスアー 抗ｃｄ３抗体製剤
EP3178850B1 (en) 2005-10-11 2021-01-13 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
AU2006301426A1 (en) * 2005-10-11 2007-04-19 Ablynx N.V. NanobodiesTM and polypeptides against EGFR and IGF-IR
EP1957099B1 (en) 2005-11-07 2015-03-25 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
JP6088723B2 (ja) 2005-11-23 2017-03-01 ジェネンテック， インコーポレイテッド Ｂ細胞アッセイに関する組成物及び方法。
CA2632424A1 (en) 2005-12-06 2007-06-14 Domantis Limited Bispecific ligands with binding specificity to cell surface targets and methods of use therefor
EA022780B1 (ru) 2006-04-05 2016-03-31 Дзе Рокфеллер Юниверсити СПОСОБ ПОВЫШЕНИЯ ПРОТИВОВОСПАЛИТЕЛЬНОЙ АКТИВНОСТИ И СНИЖЕНИЯ ЦИТОТОКСИЧЕСКОЙ АКТИВНОСТИ ПРЕПАРАТА IgG
WO2007117600A2 (en) 2006-04-07 2007-10-18 Macrogenics, Inc. Combination therapy for treating autoimmune diseases
EP2079483A4 (en) 2006-07-29 2010-10-20 Robert Lamar Bjork Jr BISPECIFIC MONOCLONAL ANTIBODIES (SPECIFIC FOR CD3 AND CD11B) THERAPEUTIC MEDICAMENTS
JP2010502220A (ja) * 2006-09-05 2010-01-28 メダレックス インコーポレーティッド 骨形態形成タンパク質およびその受容体に対する抗体ならびにその使用方法
SG10201808730VA (en) 2007-04-03 2018-11-29 Amgen Res Munich Gmbh Cross-species-specific binding domain
RU2769948C2 (ru) 2007-04-03 2022-04-11 Эмджен Рисерч (Мьюник) Гмбх CD3-Эпсилон-связывающий домен с межвидовой специфичностью
KR101626988B1 (ko) 2007-04-03 2016-06-02 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 이중특이적인 결합제들
CA2688834C (en) 2007-06-01 2020-01-07 Ronald Buelow Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
CA2720682A1 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
WO2010037838A2 (en) 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
CA2738566C (en) 2008-10-01 2024-04-30 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
BRPI0919840B1 (pt) 2008-10-01 2023-02-28 Amgen Research (Munich) Gmbh Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende
JP6126782B2 (ja) 2008-10-01 2017-05-10 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体
PL2406284T3 (pl) 2009-03-10 2017-09-29 Biogen Ma Inc. Przeciwciała anty-bcma
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
RU2724663C2 (ru) * 2010-02-08 2020-06-25 Ридженерон Фармасьютикалз, Инк. Мышь с общей легкой цепью
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
WO2012122528A1 (en) * 2011-03-10 2012-09-13 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
EP4338754A3 (en) 2011-05-27 2024-07-10 Glaxo Group Limited Antigen binding proteins
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
SG11201406346SA (en) 2012-04-20 2014-11-27 Emergent Product Dev Seattle Cd3 binding polypeptides
BR112014032916A2 (pt) * 2012-06-28 2017-08-01 Pfizer anticorpos anti-fármacos e usos destes para o monitoramento de fármaco
WO2014022540A1 (en) * 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US10002206B2 (en) 2012-10-26 2018-06-19 Saturn Licensing Llc Information processing device and information processing method
EP2914628A1 (en) 2012-11-01 2015-09-09 Max-Delbrück-Centrum für Molekulare Medizin An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
PL3653049T3 (pl) * 2012-12-14 2024-02-26 Omniab, Inc. Polinukleotydy kodujące przeciwciała gryzoni z ludzkimi idiotypami i zwierzęta je zawierające
EP2762496A1 (en) * 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
US9963513B2 (en) * 2013-02-05 2018-05-08 Engmab Sàrl Method for the selection of antibodies against BCMA
WO2015066450A1 (en) 2013-10-31 2015-05-07 Sanofi Specific anti-cd38 antibodies for treating human cancers
SG10201909806SA (en) 2013-11-04 2019-11-28 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
WO2015095412A1 (en) * 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
DK3105252T3 (da) 2014-02-12 2019-10-14 Michael Uhlin Bispecifikke antistoffer til anvendelse ved stamcelletransplantation
TWI754319B (zh) * 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
HRP20200164T1 (hr) 2014-03-28 2020-05-01 Xencor, Inc. Bispecifična protutijela koja se vežu na cd38 i cd3
EP3172237A2 (en) 2014-07-21 2017-05-31 Novartis AG Treatment of cancer using humanized anti-bcma chimeric antigen receptor
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
CN114774466A (zh) 2014-10-22 2022-07-22 克雷森多生物制剂有限公司 转基因小鼠
EP3023437A1 (en) * 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
CA2968162A1 (en) * 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag Common light chains and methods of use
DK3628687T3 (da) 2014-12-12 2021-10-18 2Seventy Bio Inc Kimære bcma-antigenreceptorer
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
GB201500461D0 (en) 2015-01-12 2015-02-25 Cresendo Biolog Ltd Therapeutic molecules
EP3056512A1 (en) * 2015-02-10 2016-08-17 Medizinische Universität Wien Antibody construct
CN106211261B (zh) 2015-04-10 2020-10-16 中兴通讯股份有限公司 信息处理方法及通信节点
EP3297729A4 (en) 2015-05-20 2019-04-10 Janssen Biotech, Inc. ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF LIGHT-CHAINED AMYLOIDOSES AND OTHER CD38-POSITIVE HEMATOLOGICAL MALIGNITIES
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
HRP20201375T1 (hr) 2015-08-17 2020-11-27 Janssen Pharmaceutica Nv ANTI-BCMA ANTITIJELA, BISPECIFIČNI ANTIGEN VEŽUĆE MOLEKULE KOJE SE VEŽU ZA BCMA i CD3, I NJIHOVE UPOTREBE
CN108884162A (zh) 2015-11-10 2018-11-23 汉堡-埃普多夫大学医学中心 针对cd38的抗原结合多肽
KR20230129583A (ko) 2016-06-21 2023-09-08 테네오바이오, 인코포레이티드 Cd3 결합 항체
KR102702078B1 (ko) 2016-08-24 2024-09-04 테네오바이오, 인코포레이티드 변형된 중쇄-단독 항체를 생산하는 형질전환 비-인간 동물
IL265321B2 (en) * 2016-09-14 2024-01-01 Teneobio Inc Cd3 binding antibodies
MX2019007379A (es) 2016-12-21 2019-09-18 Teneobio Inc Anticuerpos anti-bcma unicamente de cadena pesada.
IL271194B2 (en) 2017-06-20 2024-10-01 Teneobio Inc Anti-bcma heavy chain-only antibodies
EP3642236A1 (en) 2017-06-20 2020-04-29 TeneoOne, Inc. Anti-bcma heavy chain-only antibodies
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
KR20250012203A (ko) 2017-06-30 2025-01-23 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 인간 도메인을 갖는 항-b 세포 성숙화 항원 키메라성 항원 수용체
WO2019126756A1 (en) 2017-12-22 2019-06-27 Teneobio, Inc. Heavy chain antibodies binding to cd22
KR20200104364A (ko) * 2017-12-27 2020-09-03 테네오바이오, 인코포레이티드 Cd3-델타/엡실론 이형이량체 특이적 항체
MX2020012561A (es) * 2018-05-24 2021-01-29 Ayala Pharmaceuticals Inc Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiazepinona e inmunoterapeuticos y metodos de uso de las mismas.
MX2021000708A (es) 2018-07-20 2021-03-25 Teneobio Inc Anticuerpos de cadena pesada que se unen al cd19.
WO2020061478A2 (en) 2018-09-21 2020-03-26 Teneobio, Inc. Methods for purifying heterodimeric, multispecific antibodies
AU2019367218A1 (en) 2018-10-26 2021-06-03 TeneoFour, Inc. Heavy chain antibodies binding to CD38
US12180298B2 (en) 2019-04-05 2024-12-31 Teneobio, Inc. Heavy chain antibodies binding to PSMA
UY38748A (es) * 2019-06-14 2021-01-29 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
WO2021222578A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
US20210403587A1 (en) 2020-04-29 2021-12-30 Teneobio, Inc. Methods of treating multiple myeloma
JP7625007B2 (ja) * 2020-04-29 2025-01-31 テネオバイオ， インコーポレイテッド 重鎖定常領域が修飾された多重特異性重鎖抗体
US20220235380A1 (en) * 2021-01-26 2022-07-28 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
US20230192843A1 (en) * 2021-10-14 2023-06-22 Teneobio, Inc. Mesothelin binding proteins and uses thereof

Also Published As

Publication number Publication date
EP3512549A4 (en) 2020-06-17
CL2021003289A1 (es) 2022-07-15
CR20190198A (es) 2019-10-11
MX2024011616A (es) 2024-09-30
RU2022103374A (ru) 2022-03-02
RS65595B1 (sr) 2024-06-28
JP7431868B2 (ja) 2024-02-15
KR102507537B9 (ko) 2025-01-10
PE20241349A1 (es) 2024-07-03
JP2019536430A (ja) 2019-12-19
EP4417263A2 (en) 2024-08-21
KR20250088655A (ko) 2025-06-17
IL265321B2 (en) 2024-01-01
JP7521729B2 (ja) 2024-07-24
IL290517B2 (en) 2024-12-01
KR20190052048A (ko) 2019-05-15
MX2024011615A (es) 2024-09-30
HUE066651T2 (hu) 2024-08-28
JP7321303B2 (ja) 2023-08-04
JP2024023251A (ja) 2024-02-21
DOP2022000233A (es) 2022-11-30
EP3512549A1 (en) 2019-07-24
SI4050034T1 (sl) 2024-07-31
IL313895A (en) 2024-08-01
WO2018052503A1 (en) 2018-03-22
CO2019003706A2 (es) 2019-06-28
JP2023156342A (ja) 2023-10-24
BR122022002481A2 (es) 2019-06-11
BR122022002481A8 (pt) 2023-02-07
MY200988A (en) 2024-01-27
EP4050034A1 (en) 2022-08-31
US11421027B2 (en) 2022-08-23
CR20220578A (es) 2023-01-17
JP2024023252A (ja) 2024-02-21
AU2017327723A1 (en) 2019-05-02
RU2019111037A (ru) 2020-10-15
DOP2019000059A (es) 2019-06-16
SA522431672B1 (ar) 2023-11-12
JP2024153676A (ja) 2024-10-29
JP2022061993A (ja) 2022-04-19
IL265321A (en) 2019-05-30
LT4050034T (lt) 2024-06-10
US20230082151A1 (en) 2023-03-16
FI4050034T3 (fi) 2024-06-10
DOP2023000165A (es) 2023-10-15
UA126384C2 (uk) 2022-09-28
IL290517B1 (en) 2024-08-01
DK4050034T3 (da) 2024-06-03
IL290517A (en) 2022-04-01
CL2022003769A1 (es) 2023-07-21
IL265321B1 (en) 2023-09-01
BR112019004873A2 (pt) 2019-06-11
ES2980623T3 (es) 2024-10-02
ECSP19026304A (es) 2019-06-30
AU2022201278B2 (en) 2022-04-21
HRP20240767T1 (hr) 2024-09-13
KR20220032640A (ko) 2022-03-15
ZA202203250B (en) 2022-05-25
CL2021003290A1 (es) 2022-07-15
KR20240044520A (ko) 2024-04-04
KR102505681B1 (ko) 2023-03-06
CN114395048A (zh) 2022-04-26
JP2022061992A (ja) 2022-04-19
EP4050034B1 (en) 2024-05-08
KR20230035706A (ko) 2023-03-14
AU2017327723B2 (en) 2022-11-17
US20200048348A1 (en) 2020-02-13
US11505606B2 (en) 2022-11-22
CN109843325A (zh) 2019-06-04
MX2019002967A (es) 2019-07-04
MX2022002018A (es) 2022-03-11
CR20220408A (es) 2022-10-20
EP4417263A3 (en) 2024-11-20
JP7030109B2 (ja) 2022-03-04
CL2019000643A1 (es) 2019-08-09
KR102507537B1 (ko) 2023-03-08
CN109843325B (zh) 2023-10-03
CN117603353A (zh) 2024-02-27
PH12019500545A1 (en) 2019-07-29
CA3036550A1 (en) 2018-03-22
US20220025047A1 (en) 2022-01-27
SA523442262B1 (ar) 2024-05-19
AU2022201278A1 (en) 2022-03-17
PT4050034T (pt) 2024-05-27
JP7521728B2 (ja) 2024-07-24
PL4050034T3 (pl) 2024-07-22
CN114395048B (zh) 2025-01-28
US20230272075A1 (en) 2023-08-31
RU2019111037A3 (es) 2020-11-26

Similar Documents

Publication Publication Date Title
PE20190976A1 (es) Anticuerpos de union a cd3
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
AR109715A1 (es) Anticuerpos anti-cd27
CL2023002239A1 (es) Anticuerpos de b7-h4 y métodos para usarlos
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
CO2018013500A2 (es) Anticuerpos anti-pd-l1 y usos de los mismos
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
PE20220142A1 (es) Anticuerpos de cadena pesada que se unen al psma
PE20200384A1 (es) Metodo de fabricacion de anticuerpos bispecificos, anticuerpos bispecificos y uso terapeutico de dichos anticuerpos
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
PE20190120A1 (es) Moleculas de union a bcma y metodos de uso de las mismas
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
PE20181451A1 (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
PE20181044A1 (es) Anticuerpos anti-pd-1 y composiciones
PE20180249A1 (es) Anticuerpos neutralizadores anti-ccl20
EA201691925A1 (ru) Биспецифические антитела, которые связываются с cd38 и cd3
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
FI3389699T3 (fi) Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja
PE20081478A1 (es) Anticuerpos cd44
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
EA202191380A1 (ru) Антитела к альфа-синуклеину и их применение
ME02678B (me) Antitijela na ox-40 i postupci njihove primjene